ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2018
Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case-control study.Scientific reports · 2021Trial
- Dietary metabolomic determinants of frailty through inflammation in the Canadian Longitudinal Study on Aging.npj aging · 2026Article
- Exploring gut microbiota mechanisms in frailty induced by 5-hydroxymethylfurfural: evidence from mouse models and Mendelian randomization.Nutrition & metabolism · 2026Article
- Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men.Journal of cachexia, sarcopenia and muscle · 2024Article
- Shared plasma metabolomic profiles of cognitive and mobility decline predict future dementia.GeroScience · 2024Article
- Review
- Lipid remodeling of adipose tissue in metabolic health and disease.Experimental & molecular medicine · 2023Review
- Fatty acid amides as potential circulating biomarkers for sarcopenia.Journal of cachexia, sarcopenia and muscle · 2023Article
- Ceramide in cerebrovascular diseases.Frontiers in cellular neuroscience · 2023Review
- Metabolites Associated with Memory and Gait: A Systematic Review.Metabolites · 2022Review
- Lipids as Regulators of Cellular Senescence.Frontiers in physiology · 2022Review
- Plasma Ceramides and Risk of Impaired Lower-Extremity Function in Older Adults: A Nested Case-Control Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Implications of Sphingolipids on Aging and Age-Related Diseases.Frontiers in aging · 2021Review
- Article
- The role of lipid metabolism in aging, lifespan regulation, and age-related disease.Aging cell · 2019Review
- Article
- Article
- Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Sarcosine Is Uniquely Modulated by Aging and Dietary Restriction in Rodents and Humans.Cell reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Background: Disrupted gait has been associated with an increased risk of frailty, disability, and death, but the causal molecular pathways are not well understood. Sphingolipids, including ceramides, are associated with multiple age-related diseases. Ceramides promote atrophy, necrosis, and proteolysis in cellular and animal models, and ceramide C16:0 levels are negatively correlated with muscle mass in men. However, there is a paucity of evidence examining sphingolipids and physical function. Methods: We examined the cross-sectional association between plasma ceramides, sphingosine-1-phosphate (S1P), and ceramide/S1P ratios and gait, a robust measure of physical function, in 340 clinically normal participants aged 70 years and older enrolled in the Mayo Clinic Study of Aging. GAITRite® instrumentation was used to measure gait speed, cadence, step width, double support time, and intra-individual stride time variability. Based on previous studies, we hypothesized that higher plasma levels of ceramide C16:0 would be associated with worse gait. Results: Multivariable adjusted linear regression models revealed that higher levels of ceramide C16:0 were associated with slower gait speed, decreased cadence, and increased double support time. Conclusions: These results suggest an association between plasma ceramide C16:0 and physical function. Longitudinal studies are needed to determine whether elevated ceramide C16:0 can be utilized as a prognostic marker for functional decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.